248
Views
9
CrossRef citations to date
0
Altmetric
Letter

Impact of palifermin on mucosal toxicity in autologous stem cell transplants using busulfan–melphalan conditioning chemotherapy for Hodgkin and non-Hodgkin lymphoma

, , , , &
Pages 1415-1416 | Received 15 Aug 2011, Accepted 23 Dec 2011, Published online: 31 Jan 2012

References

  • Grigg A, Clarke K, Szer J. Prolonged disease-free survival after autografting for chemosensitive non-bulky low grade non-Hodgkin's lymphoma. Leuk Lymphoma 2000;39:283–290.
  • Grigg A, Stone J, Milner A, . Phase II study of autologous stem cell transplant using busulfan-melphalan chemotherapy-only conditioning followed by interferon for relapsed poor prognosis follicular non-Hodgkin lymphoma. Leuk Lymphoma 2010;51: 641–649.
  • Elting L, Shih Y, Stiff P, . Economic impact of palifermin on the costs of hospitalization for autologous haemopoietic stem-cell transplant: analysis of phase 3 trial results. Biol Blood Marrow Transplant 2007;13:806–813.
  • Stiff P, Emmanouilides C, Bensinger W, . Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the haemopoietic stem-cell transplantation setting. J Clin Oncol 2006;24:5186–5193.
  • Horsley P, Bauer J, Mazkowiack R, . Palifermin improves severe mucositis swallowing problems, nutritional impact symptoms, and length of stay in patients undergoing hematopoietic stem cell transplantation. Support Care Cancer 2007;15:105–109.
  • Tsirigotis P, Triantafyllou K, Girkas K, . Keratinocyte growth factor is effective in the prevention of intestinal mucositis in patients with hematological malignancies treated with high-dose chemotherapy and autologous hematopoietic SCT: a video-capsule endoscopy study. Bone Marrow Transplant 2008;42:337–343.
  • Svanberg A, Birgegard G, Ohrn K. Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy - a randomized controlled trial. Support Care Cancer 2007;15:1155–1161.
  • Bradstock K, Matthews J, Young G, . Effects of glycosylated recombinant human granulocyte colony-stimulating factor after high-dose cytarabine-based induction chemotherapy for adult acute myeloid leukaemia. Leukemia 2001;15:1331–1338.
  • Dean R, Pohlman B, Sweetenham J, . Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with bulsulfan, cyclophosphamide and etoposide. Br J Haematol 2009;148:226–234.
  • Andersson B, Kashyap A, Gian V, . Conditioning therapy with intravenous busulfan and cyclophosphamide (IVBuCy2) for hematologic malignancies prior to allogeneic stem cell transplan tation: a phase II study. Biol Blood Marrow Transplant 2002;8: 145–154.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.